Oct 30, 6:05 AM ET
BrightSpring Health Services reported third quarter 2026 net revenue of $4.21 billion and net income from continuing operations of $101 million, representing significant growth compared to the same period in 2025. Driven by strong performance across its pharmacy and provider businesses, the company also raised its full-year 2026 financial guidance for revenue and Adjusted EBITDA.
- Net revenue for the third quarter of 2026 reached $4,213 million, up 26.4% from $3,334 million in the third quarter of 2025.
- Adjusted EBITDA for the third quarter of 2026 increased 42.0% to $228 million compared to $160 million in the prior-year period.
- Full-year 2026 revenue guidance was increased to a range of $15,900 million to $16,125 million, and Adjusted EBITDA guidance was raised to $850 million to $860 million.
Read the filing on SEC.gov ↗
Jul 31, 6:05 AM ET
BrightSpring reported second quarter 2026 net revenue of $3.87 billion, up 23.0% from a year earlier, and net income of $87 million compared with $9 million in the second quarter of 2025. The company also raised its full-year 2026 revenue and Adjusted EBITDA guidance, which excludes the Community Living business it divested on March 30, 2026. For shareholders, the quarter shows higher revenue and profit and a higher full-year outlook.
- Q2 2026 net revenue of $3,873 million, up 23.0% from $3,148 million; gross profit of $493 million, up 31.5%
- Net income of $87 million vs. $9 million in Q2 2025; diluted EPS of $0.38 vs. $0.13 attributable to common shareholders
- Full-year 2026 revenue guidance raised to $15,100 million to $15,425 million; Adjusted EBITDA guidance raised to $820 million to $845 million
- Leverage fell to 2.15x at June 30, 2026, from 2.27x at March 31, 2026, after a $300.0 million First Lien Facility paydown
Read the filing on SEC.gov ↗
Jun 12, 4:05 PM ET
BrightSpring Health Services appointed Dr. Nigam H. Shah as a Class III director on June 11, 2026, increasing the Board from seven to eight members. Dr. Shah also joined the Quality and Compliance Committee, and the filing discloses no related-party transactions with him.
- Board increased from seven to eight members on June 11, 2026, to fill the new seat with Dr. Shah
- Dr. Shah is a Stanford University professor and Chief Data Scientist at Stanford Healthcare
- Dr. Shah will receive director compensation under company policy and an indemnification agreement is planned
- Press release dated June 12, 2026 furnished as Exhibit 99.1
Read the filing on SEC.gov ↗
Jun 5, 4:05 PM ET
Selling stockholders, including KKR Phoenix Aggregator L.P. and management, sold 14,999,771 BrightSpring common shares in an underwritten offering priced at $58.75 per share, with closing on June 5, 2026. The company did not receive offering proceeds, except cash from option exercises by management sellers, but it separately bought back 1,026,465 shares from the underwriter, which shareholders should note as a change in the share count and float.
- Offering: 14,999,771 shares of common stock sold by selling stockholders at $58.75 per share, under a June 3, 2026 underwriting agreement with Goldman Sachs & Co. LLC
- Company repurchase: BrightSpring bought 1,026,465 shares from the underwriter as part of the offering; the underwriter received no fees on these shares
- Proceeds: the company received no offering proceeds beyond cash from management stock option exercises
- Filing: offering made under a Form S-3ASR shelf registration filed June 10, 2025; closing occurred June 5, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.